Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Expected to Announce Quarterly Sales of $8.31 Million

Wall Street brokerages expect Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) to report $8.31 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Alpine Immune Sciences’ earnings. The highest sales estimate is $15.33 million and the lowest is $4.60 million. Alpine Immune Sciences reported sales of $7.19 million in the same quarter last year, which would suggest a positive year over year growth rate of 15.6%. The business is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Alpine Immune Sciences will report full-year sales of $66.15 million for the current year, with estimates ranging from $37.00 million to $102.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $40.07 million, with estimates ranging from $32.00 million to $45.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.06). Alpine Immune Sciences had a negative net margin of 139.41% and a negative return on equity of 46.87%.

Several brokerages have recently commented on ALPN. Zacks Investment Research lowered Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, March 22nd. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Alpine Immune Sciences in a research report on Friday, May 13th. Oppenheimer dropped their price objective on Alpine Immune Sciences from $19.00 to $17.00 in a research report on Monday, March 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Alpine Immune Sciences in a research report on Tuesday.

Shares of Alpine Immune Sciences stock opened at $7.95 on Thursday. The firm has a market cap of $241.11 million, a P/E ratio of -4.47 and a beta of 1.74. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02. Alpine Immune Sciences has a 12 month low of $6.00 and a 12 month high of $15.14. The stock’s fifty day moving average price is $8.58 and its 200-day moving average price is $9.94.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Ensign Peak Advisors Inc boosted its holdings in Alpine Immune Sciences by 50.9% in the first quarter. Ensign Peak Advisors Inc now owns 110,017 shares of the biotechnology company’s stock worth $987,000 after acquiring an additional 37,087 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Alpine Immune Sciences by 70.8% in the first quarter. Goldman Sachs Group Inc. now owns 22,850 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 9,471 shares in the last quarter. State Street Corp boosted its holdings in Alpine Immune Sciences by 7.1% in the first quarter. State Street Corp now owns 220,621 shares of the biotechnology company’s stock worth $1,979,000 after acquiring an additional 14,609 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new stake in Alpine Immune Sciences in the first quarter worth about $3,016,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Alpine Immune Sciences in the first quarter worth about $37,546,000. 77.00% of the stock is owned by institutional investors and hedge funds.

About Alpine Immune Sciences (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Featured Stories